In patients with mild to moderate Alzheimer's disease, Cerebrolysin improved clinical global impression versus placebo.
In plain wordsIn patients with mild to moderate Alzheimer's disease, Cerebrolysin improved overall clinical status more than placebo.
- Peptide
- Cerebrolysin
- Outcome
- IncreaseClinical global impression
- Study
n: not reported in source
- Comparator
- Placebo
- Outcome group
- Cognition and memory · Nervous system and cognition
- Studied dose
- 30 ml daily on five consecutive days of each week · infusion · 4 weeksAs given in this study (human).
Measurements
- log(OR)
- 1.1799
- Cerebrolysin versus placebo
- 95% confidence interval
- 0.7463 to 1.6135
- log(OR)
- p value for clinical global impression
- < 0.05
- Cerebrolysin versus placebo, clinical global impression after 4 weeks
Source sentences
Compared with placebo, log(OR) was 1.1799, and 95% confident interval was 0.7463-1.6135 (P < 0.05), indicating that Cerebrolysin could significantly improve the clinical global impression in patients with mild to moderate AD.
2 context sentences(design, population, supporting numbers)
An infusion with Cerebrolysin for 4 weeks (30 ml Cerebrolysin daily on five consecutive days of each week) led to a significant improvement of the clinical global impression.
Available data on clinical global impression, cognitive performance and activities of daily living were extracted from 6 randomized double-blind placebo-controlled clinical trials and combined with standard meta-analysis methods.